Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
Asian Pac J Cancer Prev ; 14(10): 5687-92, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-24289563

RESUMO

Type 2 diabetes mellitus (T2DM) has contributed to advanced breast cancer development over the past decades. However, the mechanism underlying this contribution is poorly understood. In this study, we determined that high glucose enhanced proteasome activity was accompanied by enhanced proliferation, migration and invasion, as well as suppressed apoptosis, in human breast cancer MCF-7 cells. Proteasome inhibitor bortezomib (BZM) pretreatment mitigated high glucose-induced MCF-7 cell growth and invasion. Furthermore, high glucose increased protein kinase C delta (PKC?)-phosphorylation. Administration of the specific PKC? inhibitor rottlerin attenuated high glucose-stimulated cancer cell growth and invasion. In addition, PKC? inhibition by both rottlerin and PKC? shRNA significantly suppressed high glucose-induced proteasome activity. Our results suggest that PKC?-dependent ubiquitin proteasome system activation plays an important role in high glucose- induced breast cancer cell growth and metastasis.


Assuntos
Neoplasias da Mama/tratamento farmacológico , Movimento Celular/efeitos dos fármacos , Proliferação de Células/efeitos dos fármacos , Glucose/farmacologia , Complexo de Endopeptidases do Proteassoma/efeitos dos fármacos , Proteína Quinase C-delta/metabolismo , Ubiquitina/metabolismo , Acetofenonas/farmacologia , Apoptose/efeitos dos fármacos , Benzopiranos/farmacologia , Ácidos Borônicos/farmacologia , Bortezomib , Neoplasias da Mama/metabolismo , Linhagem Celular Tumoral , Feminino , Glucose/metabolismo , Humanos , Células MCF-7 , Fosforilação/efeitos dos fármacos , Inibidores de Proteassoma/farmacologia , Proteína Quinase C-delta/antagonistas & inibidores , Pirazinas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA